155 related articles for article (PubMed ID: 28324747)
41. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience.
Lee J; Lee JC; Gromski MA; Kim HW; Kim J; Kim J; Hwang JH
Medicine (Baltimore); 2018 Dec; 97(50):e13592. PubMed ID: 30558029
[TBL] [Abstract][Full Text] [Related]
42. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.
Yamao K; Takenaka M; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Omoto S; Kamata K; Minaga K; Hagiwara S; Sakurai T; Nishida N; Chiba Y; Watanabe T; Kudo M
Intern Med; 2019 Jul; 58(14):1993-2002. PubMed ID: 30996164
[TBL] [Abstract][Full Text] [Related]
43. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Levy A; Chargari C; Huguet F; Védrine L; Deutsch E
Pancreas; 2012 Aug; 41(6):973-4. PubMed ID: 22781912
[No Abstract] [Full Text] [Related]
44. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
Kiba T; Saito Y; Otomo C; Sato M; Meguro T
Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
[TBL] [Abstract][Full Text] [Related]
45. [FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
Ishigame T; Kimura T; Tsukida S; Suzushino S; Muto M; Sato N; Kofunato Y; Okada R; Kenjo A; Shimura T; Marubashi S
Gan To Kagaku Ryoho; 2019 Apr; 46(4):754-756. PubMed ID: 31164525
[TBL] [Abstract][Full Text] [Related]
46. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
[TBL] [Abstract][Full Text] [Related]
47. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
Keum J; Lee HS; Kang H; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Bang S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):651-659. PubMed ID: 32185483
[TBL] [Abstract][Full Text] [Related]
48. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
49. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy.
Sasaki T; Isayama H; Aoki T; Tanaka M; Hamada T; Nakai Y; Sakamoto Y; Hasegawa K; Morikawa T; Fukayama M; Kokudo N; Koike K
Pancreas; 2014 Aug; 43(6):972-4. PubMed ID: 25010709
[No Abstract] [Full Text] [Related]
50. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
51. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
52. Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population.
Li X; Ma T; Zhang Q; Chen YG; Guo CX; Shen YN; Sun PW; Li GG; Gao SL; Que RS; Lou JY; Yu RS; Yuan Y; Wei QC; Wei SM; Zhang Y; Zheng L; Bai XL; Liang TB
Cancer Lett; 2017 Oct; 406():22-26. PubMed ID: 28729048
[TBL] [Abstract][Full Text] [Related]
53. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
[TBL] [Abstract][Full Text] [Related]
54. Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer.
Kræmer PC; Schmidt HH; Ladekarl M
Dan Med J; 2014 Apr; 61(4):A4819. PubMed ID: 24814594
[TBL] [Abstract][Full Text] [Related]
55. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
[TBL] [Abstract][Full Text] [Related]
56. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
Sasaki M; Ueno H; Mitsunaga S; Ohba A; Hosoi H; Kobayashi S; Ueno M; Terazawa T; Goto M; Inoue D; Namiki S; Sakamoto Y; Kondo S; Morizane C; Ikeda M; Okusaka T
Int J Clin Oncol; 2021 Nov; 26(11):2065-2072. PubMed ID: 34368921
[TBL] [Abstract][Full Text] [Related]
57. Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Canton C; Boussari O; Boulin M; Le Malicot K; Taieb J; Dahan L; Lopez A; Lepage C; Bachet JB
Oncologist; 2022 Jul; 27(7):e571-e579. PubMed ID: 35289915
[TBL] [Abstract][Full Text] [Related]
58. G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Cardot-Ruffino V; Bollenrucher N; Delius L; Wang SJ; Brais LK; Remland J; Keheler CE; Sullivan KM; Abrams TA; Biller LH; Enzinger PC; McCleary NJ; Patel AK; Rubinson DA; Schlechter B; Slater S; Yurgelun MB; Cleary JM; Perez K; Dougan M; Ng K; Wolpin BM; Singh H; Dougan SK
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344102
[TBL] [Abstract][Full Text] [Related]
59. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
Ozaki K; Hayashi H; Ikuta Y; Masuda T; Akaboshi S; Ogata K; Matumoto K; Ogawa K; Kamio T; Baba H; Takamori H
Clin J Gastroenterol; 2019 Dec; 12(6):603-608. PubMed ID: 30993652
[TBL] [Abstract][Full Text] [Related]
60. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.
Byrne JD; Jajja MRN; O'Neill AT; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Cancer Chemother Pharmacol; 2018 Jun; 81(6):991-998. PubMed ID: 29603014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
